Peptide tethered particles and methods of use
Functionalized particles with THFP or HBAP tethered liposomes address rapid drug clearance and biofilm challenges by enhancing drug retention and disrupting biofilms, providing prolonged therapeutic effects and reducing antibiotic resistance.
Patent Information
- Application Number
- PCT/US2025/014762
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-06
- Filing Date
- 2025-02-06
- Publication Date
- 2025-08-14
AI Technical Summary
Current drug delivery systems face challenges in maintaining therapeutic efficacy due to rapid drug clearance from target areas, leading to frequent administrations and increased risk of systemic side effects, while biofilms cause significant morbidity and mortality with antibiotic-resistant bacteria.
Functionalized particles, such as liposomes tethered with triple-helix forming peptides (THFP) or hyaluronic acid binding peptides (HBAP), enhance drug retention and disrupt biofilm formation by targeting specific environments and utilizing steric hindrance mechanisms.
The functionalized particles significantly prolong drug residence time and inhibit or eradicate biofilms, reducing the need for frequent injections and minimizing adverse effects, while offering a resistance-free treatment strategy.